Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
22.52
+0.03 (+0.13%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis Inc
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
February 13, 2023
From
Bristol Myers Squibb and Exelixis, Inc.
Via
Business Wire
Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
February 13, 2023
From
Exelixis, Inc.
Via
Business Wire
Looking Into Exelixis's Return On Capital Employed
February 08, 2023
Via
Benzinga
Exelixis (EXEL) Q4 2022 Earnings Call Transcript
February 08, 2023
EXEL earnings call for the period ending December 31, 2022.
Via
The Motley Fool
Earnings Outlook For Exelixis
February 06, 2023
Via
Benzinga
6 Analysts Have This to Say About Exelixis
January 11, 2023
Via
Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
February 12, 2023
These companies could grow in prominence in the coming years.
Via
The Motley Fool
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 07, 2023
From
Exelixis, Inc.
Via
Business Wire
3 No-Brainer Stocks to Buy Right Now for Less Than $25
February 04, 2023
All three healthcare stocks are showing solid long-term potential.
Via
The Motley Fool
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
February 02, 2023
From
Exelixis, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
January 26, 2023
Via
Benzinga
Is Exelixis Stock a Buy Now?
December 29, 2022
Don't be too quick to dismiss this company as a one-trick pony.
Via
The Motley Fool
Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
January 24, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis' Patent Decision In Line With Expectations, But Analysts Say Stock Overhang Could Continue
January 20, 2023
Via
Benzinga
Exelixis Announces Update on Patent Litigation with MSN Laboratories
January 19, 2023
From
Exelixis, Inc.
Via
Business Wire
7 Biotech Stocks That Will Make You Rich in 10 Years
January 18, 2023
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.
Via
InvestorPlace
What 5 Analyst Ratings Have To Say About Exelixis
December 09, 2022
Via
Benzinga
Where Exelixis Stands With Analysts
December 09, 2022
Via
Benzinga
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
January 08, 2023
From
Exelixis, Inc.
Via
Business Wire
Four Undervalued Healthcare Stocks for 2023
January 06, 2023
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
Via
MarketBeat
Exposures
COVID-19
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —
January 03, 2023
From
Exelixis, Inc.
Via
Business Wire
2 Top Biotech Stocks to Buy for the Long Haul
December 25, 2022
These mid-cap biotechs are solid long-term choices.
Via
The Motley Fool
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer
December 22, 2022
From
Exelixis, Inc.
Via
Business Wire
2 Beaten-Down Growth Stocks to Buy Before the Bull Run
December 21, 2022
These could become hot buys once investors pivot back to growth stocks.
Via
The Motley Fool
2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
December 16, 2022
Two drug developers stand out as plain-as-day bargains in the new year, while another top-performing biotech stock looks poised to disappoint.
Via
The Motley Fool
Nasdaq Bear Market: 5 Exceptionally Cheap Growth Stocks You'll Regret Not Buying on the Dip
December 10, 2022
These bargain-basement-priced growth stocks are ripe for the picking following a 38% peak decline in the Nasdaq Composite.
Via
The Motley Fool
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
December 09, 2022
Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study
Via
Benzinga
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
December 08, 2022
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
December 08, 2022
From
Exelixis, Inc.
Via
Business Wire
3 Stocks to Buy Hand Over Fist in December
December 03, 2022
These stocks could be big winners.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.